Mayday for Dual PPAR Agonists
Once-Hyped Diabetes Therapies in Their Death Throes?
KeywordsMetabolic Syndrome Pioglitazone Bezafibrate PPAR Agonist Avandia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 2.Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016–23PubMedCrossRefGoogle Scholar
© Adis Data Information BV 2006